First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation

被引：7
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, Dept Chem, San Diego, CA 92121 USA
[2] Bharath Univ, Chennai 600126, Tamil Nadu, India
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 03期
关键词：
Non-small cell lung cancer; KRAS mutation; guanosine triphosphate; guanosine diphosphate; adagrasib; sotorasib; RESISTANCE; RAS;
D O I：
10.2174/0929867330666230330122000
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRAS(G12C). It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRAS(G12C )mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.
引用
收藏
页码：266 / 272
页数：7
相关论文
共 50 条
  • [21] Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation.
    Jian, Hong
    Song, Zhenbo
    Zhang, Yiping
    Li, Kunyan
    Yang, Nong
    Moore, Melissa
    Wang, Pingli
    Zhao, Yanqiu
    Gong, Yi
    Underhill, Craig
    Kim, Sang-We
    Yang, Cheng-Ta
    Xiang, Ziyong
    Shi, Zhe
    Zhang, Ling
    Wang, Yaolin
    Lu, Shun
    CANCER RESEARCH, 2022, 82 (12)
  • [22] KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models
    Rosen, Joshua C.
    Nhu-An Pham
    Li, Quan
    Cao, Pinjiang
    Hueniken, Katrina
    Koga, Takamasa
    Radulovich, Nikolina
    Koers, Alex
    Niedbala, Michael
    Ross, Sarah
    Sacher, Adrian
    Tsao, Ming-Sound
    CANCER RESEARCH, 2024, 84 (06)
  • [23] WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Saito, Hitoshi
    Yamamori-Morita, Tomoko
    Nakao, Takehiro
    Liu, Jie
    Mori, Shunta
    Yagishita, Shigehiro
    Hamada, Akinobu
    Shinno, Yuki
    Yoshida, Tatsuya
    Horinouchi, Hidehito
    Ohe, Yuichiro
    Watanabe, Shun-Ichi
    Yatabe, Yasushi
    Kitai, Hidenori
    Konno, Satoshi
    Kobayashi, Susumu S.
    Ohashi, Akihiro
    CANCER LETTERS, 2025, 611
  • [24] Weight loss affects outcome in KrasG12C non-small cell lung cancer first line treated patients.
    Fancelli, Sara
    Caliman, Enrico
    Pillozzi, Serena
    Napolitano, Brunella
    Pieroni, Edoardo
    Mazzoni, Francesca
    Paglialunga, Luca
    Michelet, Marta Rita Gatta
    Roviello, Giandomenico
    Castiglione, Francesca
    Bartoli, Caterina
    Antonuzzo, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer
    Yang, Xuechao
    Zhang, Shu
    Yang, Yang
    Duan, Xiaoqun
    Li, Xiaochuan
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [26] In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung Cancer
    Kato, Ryoji
    Solanki, Hitendra S.
    Ozakinci, Hilal
    Desai, Bina
    Gundlapalli, Harika
    Yang, Yu Chi
    Aronchik, Ida
    Singh, Mallika
    Johnson, Joseph
    Marusyk, Andriy
    Boyle, Theresa A.
    Haura, Eric B.
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1150 - 1162
  • [27] Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States
    Zhu, Ya-Ning
    Tang, Meng
    Sun, Ke-Xin
    Gao, Bei
    Shi, Xian-Peng
    Zhang, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in KRASG12C non-small cell lung carcinoma
    Patel, Hetika V.
    Smith, Alison
    Chan, Stacia
    Kessler, Linda
    Burrows, Francis
    Malik, Shivani
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [29] KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer
    Suzuki, Shinichiro
    Yonesaka, Kimio
    CANCER SCIENCE, 2022, 113 : 1260 - 1260
  • [30] Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
    Kitai, Hidenori
    Choi, Philip H.
    Yang, Yu C.
    Boyer, Jacob A.
    Whaley, Adele
    Pancholi, Priya
    Thant, Claire
    Reiter, Jason
    Chen, Kevin
    Markov, Vladimir
    Taniguchi, Hirokazu
    Yamaguchi, Rui
    Ebi, Hiromichi
    Evans, James
    Jiang, Jingjing
    Lee, Bianca
    Wildes, David
    de Stanchina, Elisa
    Smith, Jacqueline A. M.
    Singh, Mallika
    Rosen, Neal
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345